Skip to content

Use of nebulised versus injected Tranexamic acid in treating blood in sputum:a randomised controlled trial.

Efficacy of nebulised versus intravenous Tranexamic acid in management of nonmassive haemoptysis:a randomised controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037079
Enrollment
46
Registered
2021-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J99- Respiratory disorders in diseasesclassified elsewhere

Interventions

Intervention1: Tranexamic acid 500mg(5ml) nebulised to the patient 8th hourly till haemoptysis subsides.: Control of nonmassive haemoptysis in adult patients in emergency department with nebulised Tra

Sponsors

Vasudha D
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adult patients more than 18 years of age, attending the emergency medicine department with nonmassive haemoptysis.(haemoptysis less than 200ml/day with no haemodynamic instability. Patients with more than one episode of haemoptysis (spitting of blood)in the last 24 hours.

Exclusion criteria

Exclusion criteria: 1. Massive haemoptysis( >200ml in the last 24 hours)with haemodynamic instability and/or respiratory obstruction, 2. Patients with haematemesis. 3. Patients on antiplatelet drug therapy, 4. Patients with pre-existing coagulation abnormalities, 5. Known hypersensitivity to the study drug, 6. Impaired renal functions (as evidenced by serum creatinine level more than 3mg/dl or need for renal replacement therapy), 7. Impaired hepatic function(serum bilirubin more than 2mg/dl,aspartate amino transferase greater than 3 times the normal,INR greater than 2).In case of subjects already started on treatment ,whose renal and hepatic function tests as detected by investigations above are impaired, they will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Among the patients undergoing treatment for hemoptysis, to compare the efficacy of nebulised TXA to that of intravenous TXA in 1. successful cessation of bleeding at 8 hours post administration, 2. amount of blood lost by expectoration per day 3. total dose of TXA administered for treatment success. Timepoint: Initial 8 hours and 8th hourly in the next 72 hours.

Secondary

MeasureTime frame
Complications, duration of hospital stay,need for invasive procedures, number of transfusions,to assess for relapse in bleeding,as assessed by increasing episodes of haemoptysis,fall in Hb level to below 10g/dl or falls more than 2g/dl from the baseline value.Timepoint: Initial 8 hours and 8th hourly in the next 72 hours.

Countries

India

Contacts

Public ContactVasudha D

JIPMER Puducherry

elamurugantp@gmail.com9443648918

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026